All In Biotech

Drug Trial Radar · NCT05152914

Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2

Intravitreal Enzyme Replacement Therapy to Prevent Retinal Disease Progression in Children With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)

Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

5

Planned (sponsor's estimate)

Start

Nov 1, 2021

Primary completion

Mar 4, 2026

Study completion Mar 6, 2027

Sponsor

Lead sponsor
David L Rogers, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 24 months, up to 72 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II randomized, masked, clinical trial to determine the safety and efficacy of intravitreal administration of cerliponase alfa.

Conditions

  • Neuronal Ceroid Lipofuscinosis Type 2

Interventions

  • Cerliponase AlfaDrug

    Brineura is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Monitoring for the development of unacceptable toxicity.Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nationwide Children's Hospital

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.